Abstract
We investigated the risk of colorectal cancer (CRC) in patients with Crohn’s disease (CD) using the claims data of the Korean National Health Insurance during 2006–2015. The data of 13,739 and 40,495 individuals with and without CD, respectively, were analyzed. Hazard ratios (HRs) were calculated using multivariate Cox proportional hazard regression tests. CRC developed in 25 patients (0.18%) and 42 patients (0.1%) of the CD and non-CD groups, respectively. The HR of CRC in the CD group was 2.07 (95% confidence interval (CI), 1.25–3.41). The HRs of CRC among men and women were 2.02 (95% CI 1.06–3.87) and 2.10 (95% CI, 0.96–4.62), respectively. The HRs of CRC in the age groups 0–19, 20–39, 40–59, and ≥60 years were 0.07, 4.86, 2.32, and 0.66, respectively. The HR of patients with late-onset CD (≥40 years) was significantly higher than that of those with early-onset CD (<40 years). CD patients were highly likely to develop CRC. Early-onset CD patients were significantly associated with an increased risk of CRC than matched individuals without CD. However, among CD patients, late-onset CD was significantly associated with an increased risk of CRC.
Highlights
Inflammatory bowel disease (IBD) is a group of disorders that cause chronic inflammation in the gastrointestinal tract, including Crohn’s disease (CD) and ulcerative colitis (UC).CD is associated with an increased risk of colorectal cancer (CRC)
13,739 patients were enrolled in the CD group
It has been known that there is an association between IBD and CRC, which is assumed to be promoted by a chronic inflammation-driven carcinogenic process in the intestine [11]
Summary
CD is associated with an increased risk of colorectal cancer (CRC). A previous meta-analysis showed more reduced incidence rates of CRC among IBD patients in the. The incidence rate of IBD in Asian countries, including South Korea, has progressively increased, with the rate of CD exhibiting a steeper increment than that of UC [2]. A cohort study from South Korea showed that the mean annual incidence rate of CD increased significantly from 0.06 per 100,000 inhabitants in 1986–1990 to 2.44 per 100,000 inhabitants in 2011–2015 [3]. Considering that the course of CD is greatly affected by the development of new treatments and drugs, the risk of CD-associated CRC is expected to change. It is important to understand the risk of CRC in patients who have newly developed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
